NICE have published their final recommendation (FAD) on the use of bosutinib for the treatment of adult patients with CML in England.
As expected the NICE Committee has reaffirmed the negative recommendation they made in the draft document (ACD) published earlier this year. Patients in England will continue to be able to receive treatment with bosutinib via the Cancer Drugs Fund (CDF).
What does CMLSG think of the Appraisal Committee’s decision? See David Ryner's comments in PDF below:
